These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1913509)

  • 1. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
    Higa GM; Gockerman JP; Hunt AL; Jones MR; Horne BJ
    Cancer; 1991 Oct; 68(8):1691-3. PubMed ID: 1913509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside.
    Matteucci P; Carlo-Stella C; Di Nicola M; Magni M; Guidetti A; Marchesi M; Gianni AM
    Haematologica; 2006 Feb; 91(2):255-7. PubMed ID: 16461314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of the rational use of corticosteroids eye drops for the prevention of ocular toxicity in high-dose cytosine arabinoside therapy].
    Itoh M; Aoyama T; Yamamura Y; Nakajima K; Nakamura K; Kotaki H; Matsuyama T; Saitoh T; Kami M; Chiba S; Hirai H; Yazaki Y; Iga T
    Yakugaku Zasshi; 1999 Mar; 119(3):229-35. PubMed ID: 10198598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.
    Lazarus HM; Hartnett ME; Reed MD; Murphy BF; Lass JH
    Am J Ophthalmol; 1987 Nov; 104(5):476-80. PubMed ID: 3314526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
    Gococo KO; Lazarus HM; Lass JH
    Cancer; 1992 Jun; 69(11):2866-7. PubMed ID: 1571919
    [No Abstract]   [Full Text] [Related]  

  • 6. Anterior uveitis associated with high-dose cytosine arabinoside.
    Fintelmann RE; Qian Y; Skalet A; Jeng BH
    Ocul Immunol Inflamm; 2010 Dec; 18(6):485-7. PubMed ID: 20887203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic treatment for cytosine arabinoside-induced keratoconjunctivitis.
    Patel AK; Sheehan W; Jenkins A; Lane C; Kell J
    Int Ophthalmol; 2011 Jun; 31(3):191-5. PubMed ID: 21424238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An in vitro method which assesses corneal epithelial toxicity due to antineoplastic, preservative and antimicrobial agents.
    Lazarus HM; Imperia PS; Botti RE; Mack RJ; Lass JH
    Lens Eye Toxic Res; 1989; 6(1-2):59-85. PubMed ID: 2488034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraplegia following intrathecal cytosine arabinoside.
    Wolff L; Zighelboim J; Gale RP
    Cancer; 1979 Jan; 43(1):83-5. PubMed ID: 282937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytosine arabinoside-induced vasculitis.
    Ahmed I; Chen KR; Nakayama H; Gibson LE
    Mayo Clin Proc; 1998 Mar; 73(3):239-42. PubMed ID: 9511781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
    Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effectiveness and toxicity of high-dosage Ara-C. Clinical observations in 10 cases and review of the literature].
    Morant R; Hofmann V; Honegger HP; Gmür J; Fehr J; Sauter C
    Schweiz Med Wochenschr; 1986 Oct; 116(41):1415-9. PubMed ID: 3466340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corneal and conjunctival toxicity with low-dose cytosine arabinoside.
    Barletta JP; Fanous MM; Margo CE
    Am J Ophthalmol; 1992 May; 113(5):587-8. PubMed ID: 1575237
    [No Abstract]   [Full Text] [Related]  

  • 14. Low-dose cytosine arabinoside in acute non-lymphoblastic leukemia.
    Kumar L; Kochupillai V; Dua H
    Cancer; 1989 Feb; 63(3):415-8. PubMed ID: 2912519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
    Wolach O; Itchaki G; Bar-Natan M; Yeshurun M; Ram R; Herscovici C; Shpilberg O; Douer D; Tallman MS; Raanani P
    Hematol Oncol; 2016 Mar; 34(1):28-35. PubMed ID: 25689584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone/Povidone Eye Drops versus Artificial Tears for Treatment of Presumed Viral Conjunctivitis: A Randomized Clinical Trial.
    Pinto RD; Lira RP; Abe RY; Zacchia RS; Felix JP; Pereira AV; Arieta CE; de Castro RS; Bonon SH
    Curr Eye Res; 2015 Sep; 40(9):870-7. PubMed ID: 25310347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Handling punctate keratitis resulting from systemic cytarabine.
    Friedland S; Loya N; Shapiro A
    Ann Ophthalmol; 1993 Aug; 25(8):290-1. PubMed ID: 8239322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Zittoun R; Marie JP; Zittoun J; Marquet J; Haanen C
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):139-43. PubMed ID: 3859928
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a relationship between cytarabine pharmacokinetics and keratitis?--A case report.
    Boos J; Bömelburg T; Gerding H; Jürgens H
    Int J Clin Pharmacol Ther Toxicol; 1993 Dec; 31(12):593-6. PubMed ID: 8314360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.